New combination therapy for non-Hodgkin lymphoma
Official title: Translation of a novel combination therapy approach for non-Hodgkin lymphoma
Funded at Mayo Clinic Rochester · NIH-10918057 · Data updated 2026-11-12
This study is looking at a new treatment approach for people with diffuse large B-cell lymphoma (DLBCL), a common type of cancer, to help improve how well therapies work, especially for those with advanced cases, by learning from both human and dog cases.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $643,654 |
| NIH project number | 5U01CA272257-03 |
| Project ID | NIH-10918057 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with diffuse large B-cell lymphoma, particularly those with relapsed or refractory cases.
✕Less likely to help
Patients with other types of non-Hodgkin lymphoma or those who are not experiencing relapsed or refractory disease may not benefit from this research.
What this research studies
This research focuses on developing a novel combination therapy for diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, which often has limited treatment options. The approach aims to understand the mechanisms behind immunotherapy resistance and improve treatment responses for patients with advanced forms of this cancer. By studying both human and canine cases of DLBCL, the research seeks to leverage similarities in tumor environments to enhance therapeutic strategies. The use of an engineered oncolytic virus is also being explored to provide a new avenue for treatment.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients suffering from non-Hodgkin lymphoma.
How similar studies have gone: Previous research has shown promise in using combination therapies and immunotherapy for similar cancers, indicating potential for success in this novel approach.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Naik, Shruthi — Mayo Clinic Rochester
- Study coordinator: Naik, Shruthi
Related research
Other NIH-funded projects on the same topics.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
Precision targeted radioactive antibody therapy for non-Hodgkin lymphoma
Researchers are developing more precise radioactive antibodies to treat people with CD20-positive non-Hodgkin lymphoma.
-
AI-designed drugs targeting a common lymphoma mutation (MYD88 L265P)
Researchers are using artificial intelligence to create and test new drugs that block a common MYD88 mutation found in many B‑cell non‑Hodgkin lymphomas to help people with these cancers.
-
New combination therapy for non-Hodgkin lymphoma
A virus-based combination treatment aims to boost the immune system to help people and companion dogs with relapsed or treatment-resistant diffuse large B-cell lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.